News
LYRA
5.20
+0.58%
0.03
Weekly Report: what happened at LYRA last week (0415-0419)?
Weekly Report · 4d ago
Lyra Therapeutics Announces Board and Committee Changes
TipRanks · 6d ago
Cantor Fitzgerald Reiterates Overweight on Lyra Therapeutics
Benzinga · 04/17 13:36
Weekly Report: what happened at LYRA last week (0408-0412)?
Weekly Report · 04/15 10:52
Weekly Report: what happened at LYRA last week (0401-0405)?
Weekly Report · 04/08 10:57
Weekly Report: what happened at LYRA last week (0325-0329)?
Weekly Report · 04/01 10:55
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
NASDAQ · 03/28 11:08
Weekly Report: what happened at LYRA last week (0318-0322)?
Weekly Report · 03/25 10:57
Lyra Therapeutics Is Maintained at Buy by B of A Securities
Dow Jones · 03/25 10:57
Lyra Therapeutics Price Target Cut to $11.00/Share From $12.00 by B of A Securities
Dow Jones · 03/25 10:57
B of A Securities Maintains Buy on Lyra Therapeutics, Lowers Price Target to $11
Benzinga · 03/25 10:47
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/23 14:41
Lyra Therapeutics files for $300M mixed shelf
Lyra Therapeutics files for a mixed securities shelf offering of up to $300M. The company is a biopharmaceutical company. Lyra filed a prospectus for a $300m mixed shelf offering on Friday. The stock is down 1.7% in pre-market trading.
Seeking Alpha · 03/22 17:03
Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High?
NASDAQ · 03/22 13:55
Lyra Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones · 03/22 10:48
HC Wainwright & Co. Reiterates Buy on Lyra Therapeutics, Maintains $12 Price Target
Benzinga · 03/22 10:40
Optimistic Buy Rating for Lyra Therapeutics’ LYR-210 Amidst Phase 3 Trial and Market Opportunity
TipRanks · 03/22 10:16
LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023
Lyra Therapeutics just reported results for the fourth quarter of 2023. The company reported earnings per share of -22 cents. This was above the analyst estimate of -31 cents. Lyra reported revenue of $146,000, which was 62.56% worse than the estimate.
Investorplace · 03/22 02:54
Lyra Therapeutics reports Q4 results
Research and development expenses for the fourth quarter were $12.2 million compared to $9.5 million. Cash, cash equivalents and short-term investments were $102.8 million as of December 31, 2023. Lyra Therapeutics believes existing cash is sufficient to fund operations into the first quarter of 2025.
Seeking Alpha · 03/21 21:05
Press Release: Lyra Therapeutics Reports Fourth -2-
The Company's ability to continue as a going concern; the Company's limited operating history; the fact that the Company has no approved products; the company's product candidates are in various stages of development. The Company may not be successful in its efforts to identify and successfully commercialize its product candidates. The Company's future results could differ from those indicated by the forward-looking statements in this press release.
Dow Jones · 03/21 20:01
More
Webull provides a variety of real-time LYRA stock news. You can receive the latest news about Lyra Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About LYRA
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.